Register cannot replace prospective studies in sickle cell diseaseBMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7184.671a (Published 06 March 1999) Cite this as: BMJ 1999;318:671
- A Yardumian, Consultant haematologist,
- A Olujohungbe, Senior registrar in haematology,
- K Cinkotai, Associate specialist in haematology
- North Middlesex Hospital, London N18 1QX
- Manchester Royal Infirmary, Manchester M13 9WL
EDITOR—We welcome the launch of a European register of patients with sickle cell disease treated with hydroxyurea1 and will certainly offer anonymised details of our treated patients. However, Davies and Roberts-Harwood would be the first to agree that a register collecting data retrospectively cannot address research questions in the way that formal prospective controlled studies can.
We agree that the results of Charache et al's study of hydroxyurea2 were convincing. However, there is wide clinical heterogeneity in this condition, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial